Key result
Glimepiride did not abolish the infarct-limiting effects of ischemic preconditioning (18.5% vs 43.7% in control, P<0.01) or diazoxide in isolated rat hearts, unlike glibenclamide.
Why the study?
Does glimepiride abolish the cardioprotective effects of ischemic preconditioning or diazoxide in isolated rat hearts?
Does glimepiride abolish the cardioprotective effects of ischemic preconditioning or diazoxide in isolated rat hearts?
Absolute Event Rate: 18.5% vs 43.7%
p-value: p=<0.01
Glimepiride, unlike glibenclamide, does not block the cardioprotective effects of ischemic preconditioning or mitochondrial K(ATP) channel opening in rat hearts, suggesting a potential advantage in diabetic patients with ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
May favor glimepiride over glibenclamide in diabetics at ischemic risk; extends animal data on KATP selectivity but leaves clinical relevance open.
Mocanu et al. (2001) studied Myocardial ischemia. Glimepiride vs. Control and Glibenclamide was evaluated on Infarct size (p=<0.01). Glimepiride did not abolish the infarct-limiting effects of ischemic preconditioning (18.5% vs 43.7% in control, P<0.01) or diazoxide in isolated rat hearts, unlike glibenclamide.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: